Detailed Information on Publication Record
2021
Gonadoliberin (gonadotropin uvolňující hormon), jeho agonisté a antagonisté
HOLICKÁ, Martina, Jakub VYSLOUŽIL, Kateřina KUBOVÁ, Jan MUSELÍK, David VETCHÝ et. al.Basic information
Original name
Gonadoliberin (gonadotropin uvolňující hormon), jeho agonisté a antagonisté
Name (in English)
Gonadoliberin (Gonadotropin-Releasing Hormone), Its Agonists and Antagonists
Authors
HOLICKÁ, Martina (203 Czech Republic, belonging to the institution), Jakub VYSLOUŽIL (203 Czech Republic, guarantor, belonging to the institution), Kateřina KUBOVÁ (203 Czech Republic, belonging to the institution), Jan MUSELÍK (203 Czech Republic, belonging to the institution) and David VETCHÝ (203 Czech Republic, belonging to the institution)
Edition
CHEMICKÉ LISTY, Praha, CHEMICKE LISTY, 2021, 0009-2770
Other information
Language
Czech
Type of outcome
Článek v odborném periodiku
Field of Study
30104 Pharmacology and pharmacy
Country of publisher
Czech Republic
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 0.356
RIV identification code
RIV/00216224:14160/21:00119761
Organization unit
Faculty of Pharmacy
UT WoS
000708686300004
Keywords in English
GnRH analogues; GnRH agonist; GnRH antagonist; hormones; therapy
Tags
International impact, Reviewed
Změněno: 28/8/2024 11:36, Mgr. Michal Petr
V originále
Nowadays, analogues of gonadotropin-releasing hormone are among the standard drugs in several indications, often using modern dosage forms. Globally, their market is estimated at billions of $ annually. This review article summarizes basic information on the relationship between structure and effect, pharmacology, and application of gonadotropin-releasing hormone and its synthetic analogues. Due to their properties, namely a higher efficiency and a higher binding affinity for the gonadotropinreleasing hormone receptor compared to native gonadotropin releasing hormone, the analogues have found applications in the treatment of many diseases, where it is necessary to suppress the secretion of gonadotropins and sex hormones. They are usually indicated for the treatment of cancers of various origins, premature puberty or artificial insemination. Due to their peptide nature, they are not administered orally, but require injection or intranasal administration. Compared to agonists, antagonists show faster onset of action and the absence of the so-called flareup phenomenon, i.e., temporarily increased serum levels of lutropin, follitropin and, consequently, of testosterone and estradiol.
In English
Nowadays, analogues of gonadotropin-releasing hormone are among the standard drugs in several indications, often using modern dosage forms. Globally, their market is estimated at billions of $ annually. This review article summarizes basic information on the relationship between structure and effect, pharmacology, and application of gonadotropin-releasing hormone and its synthetic analogues. Due to their properties, namely a higher efficiency and a higher binding affinity for the gonadotropinreleasing hormone receptor compared to native gonadotropin releasing hormone, the analogues have found applications in the treatment of many diseases, where it is necessary to suppress the secretion of gonadotropins and sex hormones. They are usually indicated for the treatment of cancers of various origins, premature puberty or artificial insemination. Due to their peptide nature, they are not administered orally, but require injection or intranasal administration. Compared to agonists, antagonists show faster onset of action and the absence of the so-called flareup phenomenon, i.e., temporarily increased serum levels of lutropin, follitropin and, consequently, of testosterone and estradiol.
Links
| QK1810221, research and development project |
|